Transglutaminase 6

Inhibited human neuronal transglutaminase


(inhibited TG6, recombinantly produced in insect cells)

Order
Quantity
Price
Status
250 µg 685 € available


Documents
Art. No. T064
Molecular Weight 78 kDa
Purity > 95 % by SDS-PAGE under reducing conditions
Appearance Liquid
Description Inhibited human neuronal transglutaminase may be used for immunoprecipitation and detection of autoantibodies in body fluid samples from patients suffering from autoimmune diseases like gluten sensitive neuronal disorders.
Formulation The inhibited TG6 is supplied in 10 mM Tris-HCl pH 8.2, 500 mM NaCl, 2 mM DTT, 5%Glycerol
Coating For coating of micro titer plates the addition of 10 mM Ca2+ is recommended.
Storage Store working aliquots at ≤ - 20°C. Avoid repeated freeze-thaw cycles.
The product is shipped on dry ice. Upon receipt, store immediately at ≤ -20°C.
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.
Usage in celiac disease diagnostic products may require a license for European Patent 0912898 and US Patent US 8,808,980 B2.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy